摘要
目前已批准了五种程序性死亡-1 /程序性死亡配体1(PD-L1)抑制剂用于治疗膀胱和上尿路的局部晚期或转移性尿路上皮癌。 FDA和EMA限制不适合铂类患者使用Atezolizumab和Pembrolizumab一线治疗的限制后,现在需要进行免疫组织化学PD-L1检测。 关于抗体,测试平台和评分算法的一些新出现的问题引起了人们对这些试验之间可比性和互换性的担忧。 在这篇综述中,我们集中于尿路上皮癌PD-L1检测所用算法和测定法的互换性,尿路上皮癌PD-L1检测的预测可靠性以及其他新的和即将出现的生物标记物的潜力。
关键词: PD-L1,免疫组化,尿路上皮癌,生物标志物,互换性,免疫疗法。
图形摘要
Current Drug Targets
Title:PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
Volume: 22 Issue: 2
关键词: PD-L1,免疫组化,尿路上皮癌,生物标志物,互换性,免疫疗法。
摘要: Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients, immunohistochemical PD-L1 testing is now required. Several emerging issues on antibodies, test platforms and scoring algorithms have raised concerns about the comparability and interchangeability between these assays. In this review, we have focused on the interchangeability of the used algorithms and assays for PD-L1 testing in urothelial carcinoma, on the predictive reliability of PD-L1 testing in urothelial carcinoma and the potential of other new and upcoming biomarkers.
Export Options
About this article
Cite this article as:
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives, Current Drug Targets 2021; 22 (2) . https://dx.doi.org/10.2174/1389450121666200510015216
DOI https://dx.doi.org/10.2174/1389450121666200510015216 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy Preformulation Designed to Enable Discovery and Assess Developability
Combinatorial Chemistry & High Throughput Screening Current Management of Neonatal Neuroblastoma
Current Pediatric Reviews New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells
Medicinal Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Endogenous Modulators of TRP Channels
Current Topics in Medicinal Chemistry Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Radiosynthesis of N.C.A. Sodium [18F]Fluoroacetate and Radiopharmacological Characterization in Rats and Tumor-Xenografted Mice
Current Radiopharmaceuticals DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design